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Two new antagonists of platelet-activating factor (PAF), the pyrrolothiazole derivative 52770 RP and the triazolodiaze- 
pine WEB 2086, have been studied as radioligands in intact human platelets. PHI52770 RP and PHIWEB 2086 bound 
specifically to high-affinity sites with dissociation constants (&) of 14.8 and 6.1 nM, respectively. The maximal number 
of sites for PHI52770 RP binding was approx. 15fold higher than for PH]PAF and PHIWEB 2086. In addition, C,,-PAF, 
lyso-PAF, WEB 2086 and 52770 RP had K, values which were nearly identical for both PH]PAF and PHIWEB 2086, 
whereas only 52770 RP competed for rH]52770 RP-binding sites. These results demonstrate that in human platelets the 
sites of PHIWEB 2086 binding are identical to PH]PAF-binding sites, whereas those of PHI52770 RP are not. PHIWEB 
2086 appears, therefore, to be a suitable antagonist radioligand for labelling PAF receptors. 
Platelet-activating factor; PAF antagonist; PAF receptor; Platelet 
1. INTRODUCTION 
Platelet-activating factor [PAF, 1-0-alkyl-2(R)- 
acetyl-sn-glycero-3-phosphorylcholine] has been 
implicated in several pathophysiological states in- 
cluding allergic inflammation, anaphylactic shock 
and asthma [l]. PAF induces platelet and 
neutrophil aggregation, bronchoconstriction, 
hypotension and increased vascular permeability. 
Of particular interest is the unique ability of PAF 
to cause a sustained increase in bronchial respon- 
siveness, which is a hallmark of asthma. 
Evidence is accumulating that PAF produces its 
various effects on target cells through activation of 
specific membrane receptors. By using [3H]PAF as 
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a radioligand it has been possible to demonstrate 
high-affinity specific binding sites on human and 
rabbit platelets, human neutrophils and human 
lung membranes [2]. Binding studies with [3H]PAF 
have often proved difficult because of the high 
level of nonspecific binding and the metabolism 
and uptake of the radioligand. Therefore, the 
development of specific PAF antagonists is 
necessary for further elucidation of the 
physiological role and mode of action of this 
mediator. [3H]Dihydrokadsurenone was the first 
radiolabelled antagonist used to characterise PAF 
receptors in rabbit platelet membranes [3]. Recent- 
ly, two new radiolabelled antagonists have been in- 
troduced: the pyrrolothiazole derivative 52770 RP, 
which has been shown to label PAF receptors on 
rabbit platelets [4], and the triazolodiazepine, 
WEB 2086 [5]. Here, we have investigated the 
binding of [3H]PAF and of the antagonist 
radioligands [3H]WEB 2086 and [3H]52770 RP to 
intact human platelets. 
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2. MATERIALS AND METHODS 
Human venous blood was collected into a tube containing 
l/8 vol. citrate anticoagulant and centrifuged at 160 x g for 
20 min at 22°C. The platelets were isolated by gel filtration on 
Sepharose CL-2B as described [6] and resuspended in Hepes 
buffer (10 mM Hepes, 145 mM NaCI, 1 mM MgClz, 5 mM 
KCI, 0.5 mM NazHP04, 6 mM glucose, 0.1% BSA; pH 7.4). 
Binding of the radioligands was measured in a final volume 
of 1 ml containing Hepes buffer, the radioligands at the in- 
dicated concentrations and 0.4-1.6 x 10s platelets. In competi- 
tion experiments the final concentrations of the radioligands 
were: [3H]PAF, 0.03 nM; [‘HIWEB 2086, 10 nM; [‘HI52770 
RP, 2.5 nM. Other substances were added as indicated. 
Triplicate incubations were carried out at 25°C for 90 min. 
Bound and free radioligand were separated by rapid filtration 
through Whatman GF/C glass fibre filters, pm-soaked in 1% 
BSA for 60 min. Filters were then washed twice with 4 ml ice- 
cold incubation buffer. 
[‘HIPAF (spec. act. 120 Ci/mmol) was purchased from 
Amersham International, N-(3-[2-‘H]chlorophenyl)-3-(3-pyrri- 
dinyl)-lH,3H-pyrrolo[1,2-c]thiazole 7-carboxamide ([‘HI52770 
RP, spec. act. 29 Ci/mmol) was kindly donated by RhBne- 
Poulenc Sante (Vitry-sur-Seine, France). 3-[4-([2-‘H]Chloro- 
phenyl)-9-methyl-H-thieno(3,2-~[1,2,4]triazolo[4,3-a][1,4]dia- 
600 
1 
zepin-2-y]] (Cmorpholinyl)-1-propanone ([‘HIWEB 2086, spec. 
act. 14 Ci/mmol) was kindly provided by Boehringer Ingelheim 
(FRG). c16-Pm and lyso-PAF were obtained from Bachem 
(Torrance, CA). Other substances were from standard commer- 
cial sources. 
3. RESULTS 
A representative saturation isotherm for 
i3H]52770 RP binding at 25°C is shown in fig.1. 
Non-specific binding increased linearly with 
[3H]52770 RP concentration whilst specific 
[‘HI52770 RP binding was saturable with increas- 
ing concentrations of the radioligand. Nonlinear 
curve fitting of the data gave a & of 14.8 nM for 
13H]52770 RP binding. The derived Scatchard plot 
of the data was linear, indicating a homogeneous 
population of non-interacting binding sites with a 
binding capacity (Bmax) of 3750 binding sites per 
cell (table 1). In kinetic experiments, both associa- 
tion and dissociation appeared to be monophasic, 
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Fig.1. Saturation of specific (0) and nonspecific (m) [‘HI52770 RP binding to intact human platelets (9.76 x 10’ per assay). 
Nonspecific binding was determined in the presence of 10 PM 52770 RP. (Inset) Scatchard plot of the same data. Data are means from 
triplicate experiments. 
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Table 1 
Characteristics of radioligand binding to intact human platelets 
Radioligand Kd (nM) Number of sites 
per cell 
13H]PAF 0.016 240 
[‘HIWEB 2086 6.1 260 
[3H]52770 RP 14.8 3750 
Data are taken from figs l-3 
confirming the homogeneity of the binding sites 
(not shown); from the data an association constant 
K+r of 0.92 x lo8 min-‘*M-l and a dissociation 
constant K-I of 0.94 min-’ were calculated, giving 
a kinetic Kd of 10 nM, which is in good agreement 
with Kd determined in the saturation experiments. 
The saturation isotherm for [3H]WEB 2086 
binding to human platelets is shown in fig.2. The 
Kd for [3H]WEB 2086 binding is 6.1 nM with a 
B max of 260 binding sites per cell. 
[f3HIWEB 20861 (nM) 
The saturation of t3H]PAF binding to human 
platelets in the absence and presence of either 
100 nM 52770 RP or 100 nM WEB 2086 is shown 
in fig.3. The presence of either PAF antagonist 
causes considerable flattening of the saturation 
curves. As determined by the Scatchard plot, the 
B,, value for t3H]PAF binding (240 sites/cell) 
was almost identical to that determined by 
[3H]WEB 2086 binding (260 sites/cell). The & and 
B,,,, values for [3H]PAF binding are very similar 
to those reported in 171. The & values of [3H]PAF 
binding are 0.016 nM in the absence of any an- 
tagonist and 0.155 and 0.209 nM in the presence of 
100 nM 52770 RP and 100 nM WEB 2086, respec- 
tively. These shifts in & values were used to 
calculate the affinities of the competitors. Calcula- 
tion of the data according to the Schild equation 
(KB = C/(CR - l), where C denotes the concentra- 
tion of the competitor and CR the ratio of the ap- 
parent & values in the presence and absence of the 
competitor) gives Ku values of 11.5 nM for 
Fig.2. Saturation of specific (0) and nonspecific (m) [“HIWEB 2086 binding to intact human platelets (9.6 x 10’ per assay). 
Nonspecific binding was determined in the presence of 10 ,uM WEB 2086. (Inset) Scatchard plot of the same data. Data are means 
from triplicate experiments. 
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Fig.3. Saturation of [3H]PAF binding to intact human platelets (4 x lo7 per assay) in the absence (0) and presence of 100 nM 52770 
RP (B) and 100 nM WEB 2086 (A). (Inset) Scatchard plot of the same data. Data are means from triplicate experiments. 
52770 RP and 8.3 nM for WEB 2086. These values 
are in very good agreement with the Kd values for 
the binding of the tritiated compounds derived 
from the saturation experiments. 
In order to characterise the radioligand-binding 
sites, competition experiments were performed. 
The inhibition of [3H]PAF binding by Cre-PAF, 
52770 RP and WEB 2086 is shown in fig.4. All 
compounds attain the same degree of maximal in- 
hibition of [3H]PAF binding. For all compounds 
the Hill Slope faCtOrS @I-I) are near unity, sug- 
gesting a bimolecular reaction. This also indicates 
that the inhibition of [‘H]PAF binding by these 
compounds is due to an interaction with the recep- 
tor itself. The Ki values of the compounds are close 
to the corresponding Kd values (table 2). Lyso- 
PAF, which is devoid of significant biological ac- 
tivity via PAF receptors, only weakly inhibited 
specific [3H]PAF binding. Nearly identical Ki 
values were obtained for inhibition of [3H]WEB 
2086 binding, demonstrating the identity of 
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13H]PAF- and [3H]WEB 2086-binding sites. In 
contrast, only 52770 RP inhibited [3H]52770 RP 
binding, whereas Ci6-PAF, lyso-PAF and WEB 
2086 had no effect on [3H]52770 RP binding at 
concentrations up to 10rM. 
4. DISCUSSION 
The pyrrolothiazole derivative [3H]52770 RP 
and the thienotriazolodiazepine [3H]WEB 2086 
have been introduced recently as new antagonist 
radioligands for PAF receptors. From competition 
experiments as well as from saturation experiments 
for [3H]PAF binding to intact human platelets 
reported here it is evident that both compounds act 
as competitive receptor antagonists. In direct 
radioligand-binding experiments both compounds 
bind specifically to high-affinity sites on human 
platelets. Ci6-PAF, 52770 RP and WEB 2086 have 
Ki values which are nearly identical for inhibition 
of both [‘HJPAF and [3H]WEB 2086 binding. In 
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Fig.4. Inhibition of [‘H]PAF binding to intact human platelets by Cr6-PAF (o), WEB 2086 (A) and 52770 RP (n). Slope factors (nH) 
are 1.0 for Crs-PAF, 1.02 for WEB 2086 and 1.06 for 52770 RP. Data are means from triplicate experiments. 
Table 2 
Inhibition of radioligand binding to intact human platelets 
Compound Ki (nM) 
[‘H]PAF [‘HIWEB 2086 [‘HI52770 RP 
c,d’AF 0.024 
(0.010-0.053) 
Lyso-PAF >lOOOO 
(30Vo)a 
WEB 2086 
(3.Z.2) 
52770 RP 13.8 
(6.5-29.4) 
0.019 > 10000 
(0.012-0.029) 
> 10000 > 10000 
(19Vo)a 
(4Y7.0) > 10000 
14.5 18.9 
(8.0-26.4) (12.0-29.9) 
a % inhibition at 1OrM 
Data are presented as geometric means with 95% confidence 
limits from three experiments 
contrast, only 52770 RP competed for [3H]52770 
RP-binding sites, while both PAF and WEB 2086 
have no affinity for t3H]52770 RP-binding sites. In 
addition, the Bmax value for t3H]52770 RP binding 
is about 15fold higher than those of [3H]PAF and 
[3H]WEB 2086 binding. These results clearly 
demonstrate that in human platelets the binding 
sites of [3H]WEB 2086 are identical to those of 
[3H]PAF binding, while those of [3H]52770 RP are 
not. [3H]WEB 2086 appears, therefore, to be a 
suitable antagonist radioligand for labelling PAF 
receptors. 
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